Market Cap 2.48B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 3,963,295
Avg Vol 8,686,430
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 89%
Beta 1.14
Analysts Strong Sell
Price Target $10.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
TheDrunkTrader69
TheDrunkTrader69 Jul. 6 at 5:08 PM
$ABCL $10 looks good from here.
0 · Reply
DeMampCamp
DeMampCamp Jul. 6 at 3:55 PM
$ABCL It his $7.45 this morning and knocking on door at $8 again, this stock has been incredibly resilient as of late, absolutely loving it!
1 · Reply
KryptonResearch
KryptonResearch Jul. 6 at 3:54 PM
AI-enabled healthcare/research is the most obvious massive winner… $ABCL $SLS $RXRX $IBRX $TEM etc… We take a look at a lesser known name in this space, with similar, if not greater upside potential given their ownership of the data layer. This is the next big sector, we have our pick, but there are so many names that will pay well. https://kryptonresearch.substack.com/p/blood-money
0 · Reply
SmartCapitall
SmartCapitall Jul. 6 at 3:14 PM
$ABCL price action looks too strong for the market to be bracing for a miss. When price keeps grinding like this, traders are clearly leaning toward a solid Phase 2 readout. Not a guarantee, but the tape is telling you uncertainty isn’t getting much weight here.
0 · Reply
DeMampCamp
DeMampCamp Jul. 6 at 2:26 PM
$ABCL Algos dumping to pump into tech today, I expect this to only be very short term, use these dips to add to your share count! Cheers!
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 2:22 PM
$ABCL $ABCL AbCellera Appoints Dr. Lynn Seely to its Board of Directors: “AbCellera is well positioned for growth as it moves multiple product candidates, developed by its exceptional research team and designed to bring meaningtul new treatments to patients, into early- and late-stage clinical development.", said Dr Seely
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 2:20 PM
$ABCL Most failed biotech reversals share the same pattern: weak volume + early breakout + immediate rejection $ABCL is attempting the opposite setup: strong volume + base retest + upward expansion
0 · Reply
tradersunion353
tradersunion353 Jul. 6 at 2:00 PM
$ABCL As usual sick trading personality as the stock drops clowns here get too excited they dont actually post but in drops they come out like maggots and start cheerleading Especialy DEMAMP and other few of his papers traders
0 · Reply
tradersunion353
tradersunion353 Jul. 6 at 1:53 PM
$ABCL Adding and loading buying oppurtunity selling my shirt to buy ABCL Typical Paid pumpers or papers traders patter, This POS has not delviered returns for investors for last 5-6 years. Until this reaches $15 this POS is much over hyped and under performing junk -
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jul. 6 at 1:53 PM
0 · Reply
Latest News on ABCL
AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 3 hours ago

AbCellera apponts Lynn Seely to board of directors

LYEL


AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 4 hours ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors


AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 4 weeks ago

AbCellera appoints Victor Sandor to board of directors


AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 7 weeks ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 7 weeks ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 7 weeks ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 7 weeks ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 7 weeks ago

AbCellera Biologics Slides: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 2 months ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 3 months ago

AbCellera initiated with a Buy at JonesResearch


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 4 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 4 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 6 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 8 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 8 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 10 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024


AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024


AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024


AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024


AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024


AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024


AbCellera Biologics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024


AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing


TheDrunkTrader69
TheDrunkTrader69 Jul. 6 at 5:08 PM
$ABCL $10 looks good from here.
0 · Reply
DeMampCamp
DeMampCamp Jul. 6 at 3:55 PM
$ABCL It his $7.45 this morning and knocking on door at $8 again, this stock has been incredibly resilient as of late, absolutely loving it!
1 · Reply
KryptonResearch
KryptonResearch Jul. 6 at 3:54 PM
AI-enabled healthcare/research is the most obvious massive winner… $ABCL $SLS $RXRX $IBRX $TEM etc… We take a look at a lesser known name in this space, with similar, if not greater upside potential given their ownership of the data layer. This is the next big sector, we have our pick, but there are so many names that will pay well. https://kryptonresearch.substack.com/p/blood-money
0 · Reply
SmartCapitall
SmartCapitall Jul. 6 at 3:14 PM
$ABCL price action looks too strong for the market to be bracing for a miss. When price keeps grinding like this, traders are clearly leaning toward a solid Phase 2 readout. Not a guarantee, but the tape is telling you uncertainty isn’t getting much weight here.
0 · Reply
DeMampCamp
DeMampCamp Jul. 6 at 2:26 PM
$ABCL Algos dumping to pump into tech today, I expect this to only be very short term, use these dips to add to your share count! Cheers!
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 2:22 PM
$ABCL $ABCL AbCellera Appoints Dr. Lynn Seely to its Board of Directors: “AbCellera is well positioned for growth as it moves multiple product candidates, developed by its exceptional research team and designed to bring meaningtul new treatments to patients, into early- and late-stage clinical development.", said Dr Seely
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 2:20 PM
$ABCL Most failed biotech reversals share the same pattern: weak volume + early breakout + immediate rejection $ABCL is attempting the opposite setup: strong volume + base retest + upward expansion
0 · Reply
tradersunion353
tradersunion353 Jul. 6 at 2:00 PM
$ABCL As usual sick trading personality as the stock drops clowns here get too excited they dont actually post but in drops they come out like maggots and start cheerleading Especialy DEMAMP and other few of his papers traders
0 · Reply
tradersunion353
tradersunion353 Jul. 6 at 1:53 PM
$ABCL Adding and loading buying oppurtunity selling my shirt to buy ABCL Typical Paid pumpers or papers traders patter, This POS has not delviered returns for investors for last 5-6 years. Until this reaches $15 this POS is much over hyped and under performing junk -
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jul. 6 at 1:53 PM
0 · Reply
Rastafari
Rastafari Jul. 6 at 1:48 PM
$ABCL Buying opportunity people!back the truck up. We will see $8 by COB!
0 · Reply
sogenerous
sogenerous Jul. 6 at 1:47 PM
$ABCL again by the time everyone sees its a "nice" chart with big green bars - sub 100 IQs - its too late often in the short -term and retracement looming
0 · Reply
tradersunion353
tradersunion353 Jul. 6 at 1:46 PM
$ABCL Annoying DEMAMP and other maggot paper traders with those " I want 3 doolar so i can more maggots" will be out today -- flooding the board
0 · Reply
Cryptocr7
Cryptocr7 Jul. 6 at 1:37 PM
$ABCL bios getting hit for no reason it seems today
0 · Reply
Ckkung71
Ckkung71 Jul. 6 at 1:35 PM
$ABCL Once again do not stress over short attacks they buy back soon
0 · Reply
tranq19
tranq19 Jul. 6 at 1:29 PM
$ABCL https://www.stocktitan.net/news/ABCL/ab-cellera-appoints-dr-lynn-seely-to-its-board-of-ic0eqco2b41w.html
0 · Reply
JennyRowes
JennyRowes Jul. 6 at 1:21 PM
$ABCL new director with late stage experience in women’s health and endocrinology. Good sign “Dr. Seely also served as the chief medical officer of Medivation Inc., where she led the clinical development of the oncology drug Xtandi® (enzalutamide) from first-in-human trials through global approvals, prior to its $14 billion acquisition by Pfizer Inc”
0 · Reply
Estimize
Estimize Jul. 6 at 11:03 AM
Wall St is expecting -0.14 EPS for $ABCL Q2 [Reporting 08/06 AMC] http://www.estimize.com/intro/abcl?chart=historical&metric_name=eps&utm_c
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 3:52 AM
$ABCL If $ABCL posts positive phase two results, I will name my first born daughter Abigail. She is due in August.
1 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 6 at 1:40 AM
$ABCL Healthy volume in $ABCL is exactly what traders want to see.
0 · Reply
MorganHoratio
MorganHoratio Jul. 5 at 9:31 PM
The Next Multi-Bagger Will Start as an Asymmetrical Bet $SATL at $5.43 $TE at $8.56 $SIVEF at $5.28 $OPEN at $4,90 $ABCL at $8.11 The next multi-bagger always starts as an asymmetrical bet! The tickers mentioned represent classic high-beta, high-reward asymmetric plays. We are looking at satellite imagery network SATL, energy growth play TE, tech-hardware pioneer SIVEF, real estate disrupter OPEN, and TechBio innovator ABCL. Sitting in the $4-$8 range, they face macro choppy waters but are leveraged to major thematic expansions. The beauty of asymmetry is that the downside is structurally bounded by depressed valuations, while the upside is absolutely massive once a pivotal catalyst hits. It's the ultimate setup for outsized returns. Are you adding asymmetric exposure to your portfolio right now? Which ticker here is your top pick to multi-bag first: SATL, TE, SIVEF, OPEN, or ABCL? Drop your sentiment below!
4 · Reply
StockEnginee1
StockEnginee1 Jul. 5 at 8:46 PM
$ABCL's real differentiator may be RepSeq, not a single drug candidate. The platform continuously captures antibody sequence and functional data, creating a feedback loop where more data improves AI, and better AI accelerates antibody discovery. That makes RepSeq more than a research tool—it becomes a growing data asset and potential moat. Long term, $ABCL may deserve to be valued as an AI-enabled drug discovery platform, not just a traditional biotech.
0 · Reply